Note 1 - Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Debt Securities, Available-for-sale [Table Text Block]

	March 31, 2021
					Gross		Gross
	Amortized		Accrued		Unrealized		Unrealized		Estimated
	Cost		Interest		Gains		Losses		Fair Value
Obligations of U.S. Government and its agencies	$	10,675	$	6	$	3	$	-	$	10,684
Certificates of deposit		2,758		11		1		-		2,770
Total investments	$	13,433	$	17	$	4	$	-	$	13,454

	December 31, 2020
					Gross		Gross
	Amortized		Accrued		Unrealized		Unrealized			Estimated
	Cost		Interest		Gains		Losses			Fair Value
Obligations of U.S. Government and its agencies	$	24,986	$	14	$	3	$	(3	)	$	25,000
Certificates of deposit		3,225		11		3		-			3,239
Total investments	$	28,211	$	25	$	6	$	(3	)	$	28,239

Schedule of Receivables from Collaborations [Table Text Block]

	March 31, 2021
	Billed			Unbilled		Total
U.S. Department of Health and Human Services	$	3,966		$	3,514	$	7,480
Shionogi & Co. Ltd.		(190	)		4		(186	)
Green Cross Corporation		1,157			21		1,178
Mundipharma International Holdings Limited		32			-		32
Total receivables	$	4,965		$	3,539	$	8,504

	December 31, 2020
	Billed		Unbilled		Total
U.S. Department of Health and Human Services	$	-	$	5,402	$	5,402
Shionogi & Co. Ltd.		2,037		4		2,041
Green Cross Corporation		740		21		761
Mundipharma International Holdings Limited		39		-		39
Total receivables	$	2,816	$	5,427	$	8,243

Schedule of Inventory, Current [Table Text Block]

	March 31,			December, 31
	2021			2020
Raw materials	$	101		$	206
Work-in-process		5,012			2,555
Finished goods		270			4,548
Total Inventory	$	5,383		$	7,309
Reserves		(270	)		(270	)
Total Inventory, net	$	5,113		$	7,039

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31,
	2021			2020
Product sales, net:
ORLADEYO	$	10,938		$	-
Peramivir		6,820			218
RAPIVAB		113			-
Total product sales, net		17,871			218
Royalty revenue		(897	)		1,945
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services		2,085			1,607
Torii Pharmaceutical Co., Ltd.		-			1,053
Total collaborative and other research and development revenues		2,085			2,660
Total revenues	$	19,059		$	4,823